On specific issues that are transborder and more like pandemics, there is a lot of international cooperation on the types of vaccines you would use. In a case of an emerging disease where there was a company or a therapeutic product that looked promising and that really needed to be introduced in Canada as well as in the U.S., I imagine we would be on fire; we would not be lagging behind.
We have been in a situation in the past where there has been a backlog. Particularly, for example, when you look at the number of generic products that are on the market in the U.S. versus those in Canada, these products have not been introduced into our market. But the intent now is to create an environment that is conducive to bringing in those particular products, so that we are able to have the same access to these products as the Americans, or for that matter even the Europeans.